Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, February 8, 2013
Thu, February 7, 2013 BGMO, CYCC, EADSY, IFAS, Removed From Naked Short Lists Today
February 7, 2013 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , announced today that these select companies have been Removed From the NASDAQ, AMEX, NYSE, OTCBB and Pinksheet naked short threshold lists. BERGAMO ACQUISITION CORP (OTC:BGMO), Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC), European Aeronautic Defence and Space Company EADS NV (OTC:EADSY), iShares FTSE EPRA/NAREIT Asia Index fund (NASDAQ:IFAS). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
BERGAMO ACQUISITION CORP (OTC:BGMO) - Bergamo Acquisition Corp. engages in the investment of financial instruments and companies worldwide. The company invests in a portfolio of large corporate and middle-market companies for sole acquisition and co-investment, as well as private equity funds, hedge funds, investment banks, and other institutions. It is involved in pursuing alternative energy projects in developing and underdeveloped countries. The company, through its 60% interest in Bergamo Energy Inc., provides solar energy technologies to sovereign and corporate customers in Asia. It offers solar generators for cell phone towers, solar generators for home and industry applications, and solar operated tube well water pumping systems. The company also provides turnkey solutions to developers, utilities, water districts, power plant owners, and industrial customers looking to diversify and complement their existing generation portfolio with compact solar thermal generation. Bergamo Acquisition Corp. was incorporated in 1997 and is based in Henderson, Nevada.. There is a failure to deliver in shares of BGMO
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) - Cyclacel Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of mechanism-targeted drugs to treat human cancers and other serious diseases in the United States. Its product portfolio comprises Sapacitabine, CYC682, a cell cycle modulating nucleoside analog, which is in Phase III clinical trial for the treatment of acute myeloid leukemia in the elderly, as well as in Phase II clinical trials for the treatment of myelodysplastic syndromes, non-small cell lung cancer (NSCLC), and chronic lymphocytic leukemia. The company s products also include Seliciclib, CYC202, a CDK (cyclin dependent kinase) inhibitor that is in Phase IIb clinical trial for the treatment of NSCLC; and in Phase II clinical trials to treat nasopharyngeal cancer, as well as in Phase I clinical trials in combination with Sapacitabine to treat cancer. In addition, the company s products also comprise Cell Cycle Inhibitors, which has completed Phase I trial for the treatment of autoimmune and inflammatory diseases. Its products under preclinical stage include Seliciclib, CYC065, a CDK inhibitor for the treatment of cancer; and Plk1 Inhibitors to treat cancer. Further, the company markets directly Xclair Cream for radiation dermatitis, as well as Numoisyn Liquid and Numoisyn Lozenges for xerostomia. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.. There is a failure to deliver in shares of CYCC
European Aeronautic Defence and Space Company EADS NV (OTC:EADSY) - European Aeronautic Defence and Space Company EADS N.V. engages in the manufacture and sale of commercial aircraft, civil and military helicopters, commercial space launch vehicles, missiles, military aircraft, satellites, defense systems, and defense electronics worldwide. It is also involved in the provision of services related to these activities. The company s Airbus Commercial segment develops, manufactures, markets, and sells commercial jet aircraft of approximately 100 seats; and offers aircraft conversion and related services. Its Airbus Military segment engages in the development, manufacture, marketing, and sale of military transport aircraft and special mission aircraft, as well as offers related services. The company s Eurocopter segment develops, manufactures, markets, and sells civil and military helicopters, as well as provides helicopter related services. Its Astrium segment engages in developing, manufacturing, marketing, and selling satellites, orbital infrastructures, and launchers; and offers of space related services. The company s Cassidian segment develops, manufactures, markets, and sells missiles systems, military combat aircraft, and training aircraft; and provides defense electronics and security market solutions, such as integrated systems for global border security and secure communications solutions, and logistics, as well as offers training, testing, engineering, and other related services. It is also involved in developing, manufacturing, marketing, and selling regional turboprop aircraft and aircraft components. European Aeronautic Defence and Space Company EADS N.V. was founded in 2000 and is headquartered in Leiden, the Netherlands.. There is a failure to deliver in shares of EADSY
iShares FTSE EPRA/NAREIT Asia Index fund (NASDAQ:IFAS) - iShares Trust iShares FTSE EPRA/NAREIT Asia Index Fund. There is a failure to deliver in shares of IFAS
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.
INVESTMENTS & TRADING
SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,750,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
Contact: Thomas Ronk / CEO www.BUYINS.net (800) 715-9999 tom@buyins.net
- WOPRAI
- support@woprai.com